Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma

Walid Shalata; Rachel Steckbeck; Ilya Polishchuk; Ahron Yehonatan Cohen; Keren Rouvinov; Margarita Tokar; Ashraf Abu Jama; Omar Abu Saleh; Kim Sheva; Alexander Yakobson

doi:10.3389/fonc.2023.1102330

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma

Front Oncol. 2023 Feb 14:13:1102330. doi: 10.3389/fonc.2023.1102330. eCollection 2023.

Authors

Affiliations

¹ The Legacy Heritage Center & Dr. Larry Norton Institute, Soroka Medical Center and Ben Gurion University, Beer Sheva, Israel.
² Medical School for International Health, Ben Gurion University of the Negev, Beer Sheva, Israel.
³ Internal Medicine Ward, Soroka Medical Center & Ben-Gurion University, Beer-Sheva, Israel.
⁴ Department of Dermatology and Venereology, Emek Medical Centre, Afula, Israel.

Abstract

This case report describes the occurrence of hyperbilirubinemia as a complication of metastatic melanoma. A 72-year-old male patient was diagnosed with BRAF V600E-mutated melanoma with metastases in the liver, lymph nodes, lungs, pancreas, and stomach. Due to a lack of clinical data and specific guidelines for the treatment of mutated metastatic melanoma patients with hyperbilirubinemia, a conference of specialists debated between initiating treatment or providing supportive care. Ultimately, the patient was started on the combination therapy of dabrafenib and trametinib. This treatment resulted in a significant therapeutic response via normalization of bilirubin levels and an impressive radiological response of metastases just one month post-treatment initiation.

Keywords: BRAF mutation (V600E); dabrafenib; hyperbilirubinemia; metastatic melanoma; safety; trametinib.